Recent progress of myelodysplastic syndrome: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤

ABSTRACT

The myelodysplastic syndromes (MDS),which are characterized by the presence of ineffective hematopoiesis and an increased risk of transformation to acute myeloid leukemia (AML),are a group of clonal disorders deriving from damage of the hematopoietic stem/progenitor cells.In the 56th American Society of Hematology (ASH) annual meeting,lots of new discoveries about the pathogenesis of MDS and the role of the pathogenesis in the clinical outcomes and treatment were introduced.There were also many developments in the treatment of MDS including drug therapies and Hematopoietic stem cell tranplantation (HSCT) reported in the meeting.